Abstract 15053: Serum Adipocyte Fatty Acid-binding Protein Is Associated With Chronic Kidney Disease And Coronary Lesion Severity In Type2 Diabetic Patients
Background: Chronic kidney disease (CKD) is associated with cardiovascular events. Adipocyte fatty acid-binding protein (A-FABP) has been shown to play an important role in the glucose metabolism. We investigated whether serum A-FABP could correlate with renal function and severity of coronary artery lesion in patients with type 2 diabetes.
Methods: The consecutive 191 patients with stable coronary artery disease (mean age; 69±11 years) were enrolled from inpatients who underwent coronary angiography. The severity of coronary stenosis was assessed using the scoring system. We defined CKD as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2, based on the creatinine obtained before angiography.
Results: In all subjects, serum A-FABP was significantly correlated with eGFR (r=-0.447, p<0.01) and the coronary plaque severity (r=0.157. p=0.02), besides body mass index, uric acid, HDL-C, and HOMA-IR. In diabetic patients, the associations of serum A-FABP with eGFR (r=-0.433, p<0.001) and coronary plaque severity (r=-0.292, p<0.01) remain significant; however, in non-diabetic subjects, the correlation between serum A-FABP and coronary plaque severity was no more significant (r=-0.045, p=0.651). Serum A-FABP (ng/mL) in subjects with multi-vessel disease or CKD was significantly higher than those with single-vessel disease or non-CKD (32.4±3.6 vs. 20.5±1.7, expressed as mean±S.E., p=0.02 and 42.3±5.4 vs. 23.5±2.5, p<0.01). Diabetic subjects with higher A-FABP (>20.3ng/mL) had more multi-vessel coronary artery disease and CKD than those with lower A-FABP (67% vs. 20%, p=0.02 and 39% vs. 4%, p<0.01, respectively). Multiple logistic analysis demonstrated that serum A-FABP (per doubling) was independently associated with multi-vessel coronary artery disease (odds ratio [OR] 1.89 [95% CI 1.02-3.45]; p=0.04 and CKD (OR 6.21 [1.78-21.67]; p<0.01).
Conclusion: Serum A-FABP could be a new biomarker for the renal dysfunction and the coronary atherosclerosis in type 2 diabetic patients. A-FABP might be involved in the interplay between renal dysfunction and coronary artery disease in type 2 diabetic patients.
- © 2011 by American Heart Association, Inc.